Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.

Breast cancer research and treatment - 1 Jan 2011

Siegelmann-Danieli Nava, Kurnik Daniel, Lomnicky Yossi, Vesterman-Landes Janet, Katzir Itzhak, Bialik Martin, Loebstein Ronen

Abstract excerpt

Endoxifen, the most active metabolite of the prodrug tamoxifen, is produced by cytochrome P450 CYP2D6. Breast cancer patients treated with tamoxifen who have reduced CYP2D6 activity, related to either genetic variation or drug inhibition, may have inferior outcomes. To assess the effect of concom...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Disease-Free Survival

Share to Drug Interactions

Share to Enzyme Inhibitors

Share to Neoplasm Recurrence, Local

Share to Tamoxifen

Source

Identifiers

PMID: 20593233
DOI: 10.1007/s10549-010-1008-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20593233-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.PMID 20593233Read ↗

CYP2D6 testing in breast cancer: ready for prime time?Semantic proximity Read ↗

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.Semantic proximity Read ↗

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Semantic proximity Read ↗

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.Semantic proximity Read ↗

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.Semantic proximity Read ↗

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.Semantic proximity Read ↗

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.